Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada

European Journal of Preventive Cardiology

Volumn 19, Issue 2, 2012, Pages 221-230

  Gitt, Anselm K ^a   Drexel, Heinz ^b   Feely, John ^c   Ferrières, Jean ^d   Gonzalez Juanatey, José R ^e   Thomsen, Kristian K ^f   Leiter, Lawrence A ^g   Lundman, Pia ^h   Da Silva, Pedro M ⁱ   Pedersen, Terje ^j   Wood, David ^k   Jünger, Claus ^a   Dellea, Pam S ^l   Sazonov, Vasilisa ^l   Chazelle, François ^l   Kastelein, John J P ^m  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Landeskrankenhaus Feldkirch   (Austria)

^c ST JAMES S HOSPITAL   (Ireland)

^d CHU RANGUEIL   (France)

^e Instituto de Salud Carlos III   (Spain)

^f ESBJERG HOSPITAL   (Denmark)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h DANDERYD HOSPITAL   (Sweden)

ⁱ HOSPITAL DE SANTA MARTA   (Portugal)

^j ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^k CHARING CROSS HOSPITAL   (United Kingdom)

^l MERCK RESEARCH LABORATORIES   (United States)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

Cardiovascular disease; cross sectional study; DYSIS; dyslipidemia; HDL cholesterol; hydroxymethylglutaryl CoA reductase inhibitors; LDL cholesterol; risk; triglycerides

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; EUROPE; FEMALE; HIGH RISK PATIENT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CANADA; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; EUROPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPIDS; MIDDLE AGED; PREVALENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 84861849012     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711400545     Document Type: Article

References (30)

1. The changing history. Geneva: World Health Organization ; 2004
2. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006 ; 27: 1610-1619 (Pubitemid 43954923)
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 ; 27: 1047-1053 (Pubitemid 38579764)
4. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006 ; 113: 898-918
5. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366: 1267-1278
6. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008 ; 371: 117-125
7. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 ; 110: 227-239 (Pubitemid 38924592)
8. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007 ; 28: 2375-2414
9. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 2001 ; 104: 2376-2383 (Pubitemid 33049524)
10. Gotto AM. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002 ; 144 (Suppl). S33 - S42
11. Barter PJ, Puranik R, Rye KA. New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep. 2007 ; 9: 493-498 (Pubitemid 350081421)
12. McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep. 2008 ; 10: 386-390
13. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. (EUROASPIRE Study Group). Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 ; 373: 929-940
14. Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Clin Ther. 2007 ; 29: 1671-1681 (Pubitemid 47500127)
15. Phatak H, Wentworth C, Sazonov V, Burke T. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis. 2009 ; 202: 225-233
16. Suárez C, Maiques A, Ambegaonkar BM, Melero M, Nocea G, Zhang Q, et al ISPOR 11th Annual European Congress. Athens, Greece:
17. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997 ; 80: 106-107
18. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000 ; 101: 207-213 (Pubitemid 30044262)
19. McPherson R, Frolich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and the prevention of cardiovascular disease. Can J Cardiol. 2006 ; 22: 913-927 (Pubitemid 44596492)
20. Luc G, Bard JM, Ferrières J, Evans A, Amouyel P, Arveiler D, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: The PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1155-1161 (Pubitemid 34764867)
21. Bourgault C, Davignon J, Fodor G, Gagné C, Gaudet D, Genest J, et al. Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study-Observational (CALIPSO). Can J Cardiol. 2005 ; 21: 1187-1193 (Pubitemid 43013529)
22. Bruckert E, Baccara-Dinet M, Eschwege E. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidemia: data from a pan-European survey. Diabet Med. 2007 ; 24: 388-391 (Pubitemid 46452407)
23. Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil. 2006 ; 13: 776-783 (Pubitemid 44454851)
24. Goff DC, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006 ; 113: 647-656
25. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, et al. Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006 ; 119: 676-683
26. Grant RW, Meigs JB. Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care. 2007 ; 30: 479-484 (Pubitemid 46354321)
27. Waters DD, Brotons C, Chiang CW, Ferrières J, Foody J, Jukema JW, et al. Lipid Treatment Assessment Project 2 Investigators. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009 ; 120: 28-34
28. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol. 2005 ; 60: 543-551 (Pubitemid 41532455)
29. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992 ; 85: 37-45
30. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000 ; 102: 21-27